News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
New and experimental hepatitis C treatment
Sofosbuvir plus ribavirin works well for hard-to-treat inner-city hepatitis C patients

A simple 24-week oral regimen consisting of sofosbuvir plus full-dose ribavirin cured nearly 70% of previously untreated people with genotype 1 hepatitis C, many of whom had

Published
20 March 2013
By
Liz Highleyman
New and experimental hepatitis C treatment
AbbVie interferon-free combinations cure most newly treated hepatitis C patients

All-oral regimens consisting of the HCV protease inhibitor ABT-450, a non-nucleoside polymerase inhibitor and ribavirin led to sustained response for more than 90% of previously untreated hepatitis 

Published
20 March 2013
By
Liz Highleyman
New and experimental hepatitis C treatment
Presidio Pharmaceuticals Announces Collaboration with Boehringer Ingelheim

The Parties to Initiate a Phase IIa Trial of an All-Oral Combination of Presidio’s HCV NS5A inhibitor (PPI-668) with Faldaprevir (BI201335) and BI207127 for the Treatment of Patients with Hepatitis C.

Published
13 March 2013
From
Presidio press release
New and experimental hepatitis C treatment
Adding telaprevir improves acute hepatitis C treatment for HIV-positive men

Adding telaprevir (Incivo or Incivek) to pegylated interferon and ribavirin shortens the duration of treatment and increases the likelihood of a cure for HIV-positive men with acute

Published
12 March 2013
By
Liz Highleyman
New and experimental hepatitis C treatment
Simeprevir & sofosbuvir demonstrates good early cure rate with or without ribavirin

An all-oral combination of simeprevir plus sofosbuvir, with or without ribavirin, led to an early cure for most hard-to-treat prior null responders with genotype 1 hepatitis C

Published
12 March 2013
By
Liz Highleyman
New and experimental hepatitis C treatment
Faldaprevir ups interferon response in HIV/HCV co-infection

Adding the hepatitis C virus (HCV) protease inhibitor faldaprevir (formerly BI 201335) to pegylated interferon and ribavirin led to a higher early response rate and the potential

Published
11 March 2013
By
Liz Highleyman
New and experimental hepatitis C treatment
Simeprevir pushes HCV cure rate above 75% for HIV/HCV co-infection

Adding the new hepatitis C virus (HCV) protease inhibitor simeprevir (formerly TMC435) to pegylated interferon and ribavirin cures about three-quarters of HIV/HCV co-infected people, most of them with

Published
11 March 2013
By
Liz Highleyman
Pharmaceutical industry
Pfizer stops developing hepatitis C drug

Pfizer Inc. has stopped development of an experimental hepatitis C drug, bowing out of a hotly contested industry race to introduce the next generation of treatments for the infectious liver disease.

Published
10 March 2013
From
EATG
New and experimental hepatitis C treatment
Four in Five People With HIV and Hep C on Faldaprevir Achieve Early Treatment Success

Interim results from a trial of the hep C drug faldaprevir, given to people coinfected with hep C and HIV, have shown an 80 percent early success rate.

Published
07 March 2013
From
AIDSMeds
Hepatitis C treatment
French studies report real-world data on use of telaprevir and boceprevir in people with HIV and hepatitis C co-infection

Adding boceprevir or telaprevir to interferon-based therapy showed promising indications of efficacy and acceptable safety for difficult-to-treat HIV/HCV co-infected prior non-responders in a pair of French studies presented

Published
05 March 2013
By
Liz Highleyman
← First12345...28Next →

Filter by country